Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after ...

Now in its eighth year, Built In’s Best Places to Work program celebrates the companies shaping the future of work. In a rapidly evolving AI-first job market, recognition as a Best Place to Work helps ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The ...

Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...